Focus: ResMed is a $4.2B medical device company headquartered in San Diego, CA, focused on cloud-connected devices and software for out-of-hospital care, particularly in sleep apnea, COPD, and heart failure management. With 5,001–10,000 employees, it operates as a scaled, profitable public company.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Hot — 245 jobs added in 30d
Net +245 (245 new, 0 removed). Aggressive expansion phase.
ResMed is a stable, cash-generative medical device powerhouse best suited for biomedical engineers, regulatory, commercial, and digital health professionals; limited appeal for traditional drug development careers.
Help build intelligence for ResMed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ResMed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more Smartkarma
ResMed sharpens sleep care focus with $490m software business sale - MSN
ResMed sharpens sleep care focus with $490m software business sale MSN
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care - TradingView
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care TradingView
ResMed to sell software business MatrixCare for $490 million - Reuters
ResMed to sell software business MatrixCare for $490 million Reuters
ResMed (ASX:RMD): Sleep Health Leader Tops the Sector Board With a 3.85% Advance - Kalkine
ResMed (ASX:RMD): Sleep Health Leader Tops the Sector Board With a 3.85% Advance Kalkine
S&P/ASX 200 Healthcare (ASX:XHJ) Sector Surges as CSL, Telix and ResMed Lift ASX Sentiment - Kalkine
S&P/ASX 200 Healthcare (ASX:XHJ) Sector Surges as CSL, Telix and ResMed Lift ASX Sentiment Kalkine
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo